- Home
- ZEO vs LSTA Comparison
ZEO vs LSTA Comparison
Compare ZEO & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEO
- LSTA
- Stock Information
- Founded
- ZEO 2005
- LSTA 1980
- Country
- ZEO United States
- LSTA United States
- Employees
- ZEO N/A
- LSTA 26
- Industry
- ZEO
- LSTA Misc Health and Biotechnology Services
- Sector
- ZEO
- LSTA Health Care
- Exchange
- ZEO NYSE
- LSTA Nasdaq
- Market Cap
- ZEO 55.5M
- LSTA 22.5M
- IPO Year
- ZEO N/A
- LSTA N/A
- Fundamental
- Price
- ZEO $2.49
- LSTA $2.72
- Analyst Decision
- ZEO
- LSTA Strong Buy
- Analyst Count
- ZEO 0
- LSTA 1
- Target Price
- ZEO N/A
- LSTA $15.00
- AVG Volume (30 Days)
- ZEO 89.9K
- LSTA 23.4K
- Earning Date
- ZEO 08-18-2025
- LSTA 08-11-2025
- Dividend Yield
- ZEO N/A
- LSTA N/A
- EPS Growth
- ZEO N/A
- LSTA N/A
- EPS
- ZEO N/A
- LSTA N/A
- Revenue
- ZEO $61,885,622.00
- LSTA $1,000,000.00
- Revenue This Year
- ZEO N/A
- LSTA N/A
- Revenue Next Year
- ZEO N/A
- LSTA N/A
- P/E Ratio
- ZEO N/A
- LSTA N/A
- Revenue Growth
- ZEO N/A
- LSTA N/A
- 52 Week Low
- ZEO $1.05
- LSTA $1.87
- 52 Week High
- ZEO $4.75
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- ZEO 43.01
- LSTA 52.43
- Support Level
- ZEO $2.66
- LSTA $2.34
- Resistance Level
- ZEO $2.80
- LSTA $3.09
- Average True Range (ATR)
- ZEO 0.28
- LSTA 0.25
- MACD
- ZEO -0.09
- LSTA 0.01
- Stochastic Oscillator
- ZEO 1.65
- LSTA 50.67
About ZEO ZEO ENERGY CORP
Zeo Energy Corp is a vertically integrated provider of residential solar energy systems, other energy-efficient equipment, and related services currently serving customers in Florida, Texas, Arkansas, and Missouri. Its primary business activity is selling and installing residential solar energy systems that homeowners use to supplement the amount of usable electricity required to power their homes.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.